世界の肺炎治療薬の市場規模は、2023年に22億8000万ドルと評価され、2024年から2030年にかけて9.4%のCAGRで成長すると予測されます。肺炎球菌性疾患の発生率の増加が、影響の大きい成長要因です。長年にわたり、市中感染および人工呼吸器関連細菌性肺炎の数が大幅に増加しています。分子診断とポイントオブケア検査の分野における診断技術の革新が、肺炎の診断と治療の状況を大きく変えました。ポリメラーゼ連鎖反応 (PCR) や次世代シーケンシング (NGS) などの技術を含む分子診断により、肺炎の原因となる病原体を遺伝子レベルで迅速かつ正確に特定することができます。この精度により、特定の細菌、ウイルス、または真菌の薬剤の検出が可能になり、標的療法が容易になり、抗生物質の誤用が減少します。ポイント・オブ・ケア検査は、複雑な検査インフラを必要とせずに、診療所や自宅など、患者ケアの現場で即座に診断結果を得ることができます。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Pneumonia Therapeutics Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Pneumonia Therapeutics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Pneumonia Therapeutics Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Pneumonia Therapeutics Market: Product Movement Analysis, 2023 & 2030 (USD Million)
4.3. Drugs
4.3.1. Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Vaccine
4.4.1. Vaccine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Oxygen Therapy
4.5.1. Oxygen Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Pneumonia Therapeutics Market: Infection Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Pneumonia Therapeutics Market: Infection Movement Analysis, 2023 & 2030 (USD Million)
5.3. Hospital-acquired Pneumonia (HAP)
5.3.1. Hospital-acquired Pneumonia (HAP)Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Community-acquired Pneumonia (CAP])
5.4.1. Community-acquired Pneumonia [CAP] Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Ventilator-associated Pneumonia (VAP)
5.5.1. Ventilator-associated Pneumonia (VAP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Pneumonia Therapeutics Market: Route of Administration Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Pneumonia Therapeutics Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
6.3. Oral
6.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Parenteral
6.4.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Others
6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Pneumonia Therapeutics Market: End Use Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Pneumonia Therapeutics Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
7.3. Hospital
7.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Homecare
7.4.1. Homecare Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Specialty Clinics
7.5.1. Specialty Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Others
7.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Pneumonia Therapeutics Market: Regional Estimates & Trend Analysis
8.1. Pneumonia Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
8.2. North America
8.2.1. North America Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. U.S. Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Canada Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.4. Mexico
8.2.4.1. Mexico Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.5. Europe
8.2.5.1. Europe Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.6. U.K.
8.2.6.1. U.K. Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.7. Germany
8.2.7.1. Germany Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.8. France
8.2.8.1. France Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.9. Italy
8.2.9.1. Italy Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.10. Spain
8.2.10.1. Spain Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.11. Denmark
8.2.11.1. Denmark Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.12. Sweden
8.2.12.1. Sweden Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.13. Norway
8.2.13.1. Norway Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Asia Pacific
8.3.1. Asia Pacific Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.2. China
8.3.2.1. China Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.3. Japan
8.3.3.1. Japan Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.4. India
8.3.4.1. India Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.5. South Korea
8.3.5.1. South Korea Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.6. Australia
8.3.6.1. Australia Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.7. Thailand
8.3.7.1. Thailand Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Latin America
8.4.1. Latin America Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.2. Brazil
8.4.2.1. Brazil Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.3. Argentina
8.4.3.1. Argentina Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Middle East and Africa
8.5.1. Middle East and Africa Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.2. Saudi Arabia
8.5.2.1. Saudi Arabia Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.3. UAE
8.5.3.1. UAE Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.4. South Africa
8.5.4.1. South Africa Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.5. Kuwait
8.5.5.1. Kuwait Pneumonia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Heat Map Analysis
9.4. Company Profiles
9.4.1. AstraZeneca
9.4.1.1. Participant’s Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Recent Developments/ Strategic Initiatives
9.4.2. Eli Lilly and Company
9.4.2.1. Participant’s Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Recent Developments/ Strategic Initiatives
9.4.3. F. Hoffmann-La Roche Ltd.
9.4.3.1. Participant’s Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Recent Developments/ Strategic Initiatives
9.4.4. Mylan N.V.
9.4.4.1. Participant’s Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Recent Developments/ Strategic Initiatives
9.4.5. Teva Pharmaceutical Industries Ltd.
9.4.5.1. Participant’s Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Recent Developments/ Strategic Initiatives
9.4.6. Sanofi
9.4.6.1. Participant’s Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Recent Developments/ Strategic Initiatives
9.4.7. Novartis AG
9.4.7.1. Participant’s Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Recent Developments/ Strategic Initiatives
9.4.8. Sun Pharmaceutical Industries Ltd.
9.4.8.1. Participant’s Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Recent Developments/ Strategic Initiatives
9.4.9. Aurobindo Pharma
9.4.9.1. Participant’s Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Recent Developments/ Strategic Initiatives
9.4.10. Lupin
9.4.10.1. Participant’s Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Recent Developments/ Strategic Initiatives
